Aardvark Therapeutics (AARD) vs Black Diamond Therapeutics (BDTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Black Diamond Therapeutics (BDTX) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 54.6% versus a loss of 72.5%. Black Diamond Therapeutics is the larger company by market cap ($103.7 million vs $103.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | BDTX |
|---|---|---|
| Share price | $4.71 | $1.81 |
| Market cap | $103.08M | $103.72M |
| 1-day change | -5.04% | -1.09% |
| YTD return | -64.11% | -25.51% |
| 1-year return | -72.50% | -54.64% |
| 5-year return | — | -77.87% |
| EPS (TTM) | $-3.21 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $4.94 |
| 52-week low | $3.35 | $1.60 |
| Distance from 52-week high | -72.38% | -63.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +135.88% | +452.49% |
| Average volume | 208.11K | 624.32K |
| Shares outstanding | 21.88M | 57.30M |
| Employees | 28 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BDTX has outperformed AARD by 17.9 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Healthcare · Biotechnology · 28 employees
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Healthcare · Biotechnology · 21 employees
AARD vs BDTX FAQ
Which is bigger, Aardvark Therapeutics or Black Diamond Therapeutics?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $103.72M compared with $103.08M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or BDTX?
BDTX returned -54.64% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Black Diamond Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.